Peptides Biosimilars Market Report

Europe Peptides Biosimilars Market Size, Status and Forecast 2014-2026

  • POSTDATE：Mar 20, 2020
  • PAGES：191
  • REPORT CODE：GMM514273
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Peptides Biosimilars market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 3.6% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Peptides Biosimilars Market Segmentations:

    By Player:

    • Samsung Biologics

    • Amgen

    • Pfizer

    • Mylan

    • Sandoz

    • Biocon

    • Teva Pahrmaceutical

    • Celltrion

    • Stada Arzneimittel AG

    By Type:

    • Glucagon

    • Calcitonin

    By End-User:

    • Oncology

    • Chronic Diseases

    • Autoimmune Diseases

    • Blood Disorders

    • Growth Hormone Deficiency

    • Infectious Diseases

    • Other Diseases

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Peptides Biosimilars Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Peptides Biosimilars Market Size and Growth Rate of Glucagon from 2014 to 2026

    • 1.3.2 Europe Peptides Biosimilars Market Size and Growth Rate of Calcitonin from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Peptides Biosimilars Market Size and Growth Rate of Oncology from 2014 to 2026

    • 1.4.2 Europe Peptides Biosimilars Market Size and Growth Rate of Chronic Diseases from 2014 to 2026

    • 1.4.3 Europe Peptides Biosimilars Market Size and Growth Rate of Autoimmune Diseases from 2014 to 2026

    • 1.4.4 Europe Peptides Biosimilars Market Size and Growth Rate of Blood Disorders from 2014 to 2026

    • 1.4.5 Europe Peptides Biosimilars Market Size and Growth Rate of Growth Hormone Deficiency from 2014 to 2026

    • 1.4.6 Europe Peptides Biosimilars Market Size and Growth Rate of Infectious Diseases from 2014 to 2026

    • 1.4.7 Europe Peptides Biosimilars Market Size and Growth Rate of Other Diseases from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Peptides Biosimilars Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Peptides Biosimilars by Major Types

      • 3.4.1 Market Size and Growth Rate of Glucagon

      • 3.4.2 Market Size and Growth Rate of Calcitonin

    4 Segmentation of Peptides Biosimilars Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Peptides Biosimilars by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Peptides Biosimilars for Oncology

      • 4.4.2 Market Size and Growth Rate of Peptides Biosimilars for Chronic Diseases

      • 4.4.3 Market Size and Growth Rate of Peptides Biosimilars for Autoimmune Diseases

      • 4.4.4 Market Size and Growth Rate of Peptides Biosimilars for Blood Disorders

      • 4.4.5 Market Size and Growth Rate of Peptides Biosimilars for Growth Hormone Deficiency

      • 4.4.6 Market Size and Growth Rate of Peptides Biosimilars for Infectious Diseases

      • 4.4.7 Market Size and Growth Rate of Peptides Biosimilars for Other Diseases

    5 Market Analysis by Major Regions

    • 5.1 Europe Peptides Biosimilars Production Analysis by Top Regions

    • 5.2 Europe Peptides Biosimilars Consumption Analysis by Top Regions

    • 5.3 Europe Peptides Biosimilars Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Peptides Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Peptides Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.3 France Peptides Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Peptides Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Peptides Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Peptides Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Peptides Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Peptides Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Peptides Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Production, Import, Consumption and Export Analysis

    6 Product Circulation of Peptides Biosimilars Market among Top Countries

    • 6.1 Top 5 Export Countries in Peptides Biosimilars Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Peptides Biosimilars Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Peptides Biosimilars Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Peptides Biosimilars Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Peptides Biosimilars Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Peptides Biosimilars Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Peptides Biosimilars Landscape Analysis

    • 7.1 Germany Peptides Biosimilars Landscape Analysis by Major Types

    • 7.2 Germany Peptides Biosimilars Landscape Analysis by Major End-Users

    8. UK Peptides Biosimilars Landscape Analysis

    • 8.1 UK Peptides Biosimilars Landscape Analysis by Major Types

    • 8.2 UK Peptides Biosimilars Landscape Analysis by Major End-Users

    9. France Peptides Biosimilars Landscape Analysis

    • 9.1 France Peptides Biosimilars Landscape Analysis by Major Types

    • 9.2 France Peptides Biosimilars Landscape Analysis by Major End-Users

    10. Italy Peptides Biosimilars Landscape Analysis

    • 10.1 Italy Peptides Biosimilars Landscape Analysis by Major Types

    • 10.2 Italy Peptides Biosimilars Landscape Analysis by Major End-Users

    11. Spain Peptides Biosimilars Landscape Analysis

    • 11.1 Spain Peptides Biosimilars Landscape Analysis by Major Types

    • 11.2 Spain Peptides Biosimilars Landscape Analysis by Major End-Users

    12. Poland Peptides Biosimilars Landscape Analysis

    • 12.1 Poland Peptides Biosimilars Landscape Analysis by Major Types

    • 12.2 Poland Peptides Biosimilars Landscape Analysis by Major End-Users

    13. Russia Peptides Biosimilars Landscape Analysis

    • 13.1 Russia Peptides Biosimilars Landscape Analysis by Major Types

    • 13.2 Russia Peptides Biosimilars Landscape Analysis by Major End-Users

    14. Switzerland Peptides Biosimilars Landscape Analysis

    • 14.1 Switzerland Peptides Biosimilars Landscape Analysis by Major Types

    • 14.2 Switzerland Peptides Biosimilars Landscape Analysis by Major End-Users

    15. Turkey Peptides Biosimilars Landscape Analysis

    • 15.1 Turkey Peptides Biosimilars Landscape Analysis by Major Types

    • 15.2 Turkey Peptides Biosimilars Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Landscape Analysis by Top Countries

      • 16.3.1 Denmark Peptides Biosimilars Market Volume and Growth Rate

      • 16.3.2 Finland Peptides Biosimilars Market Volume and Growth Rate

      • 16.3.3 Norway Peptides Biosimilars Market Volume and Growth Rate

      • 16.3.4 Sweden Peptides Biosimilars Market Volume and Growth Rate

      • 16.3.6 Iceland Peptides Biosimilars Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Landscape Analysis by Top Countries

      • 17.3.1 Belgium Peptides Biosimilars Market Volume and Growth Rate

      • 17.3.2 Netherlands Peptides Biosimilars Market Volume and Growth Rate

      • 17.3.3 Luxembourg Peptides Biosimilars Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Landscape Analysis by Top Countries

      • 18.3.1 Estonia Peptides Biosimilars Market Volume and Growth Rate

      • 18.3.2 Latvia Peptides Biosimilars Market Volume and Growth Rate

      • 18.3.3 Lithuania Peptides Biosimilars Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Samsung Biologics

      • 19.1.1 Samsung Biologics Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Amgen

      • 19.2.1 Amgen Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Pfizer

      • 19.3.1 Pfizer Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Mylan

      • 19.4.1 Mylan Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Sandoz

      • 19.5.1 Sandoz Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Biocon

      • 19.6.1 Biocon Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Teva Pahrmaceutical

      • 19.7.1 Teva Pahrmaceutical Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Celltrion

      • 19.8.1 Celltrion Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Stada Arzneimittel AG

      • 19.9.1 Stada Arzneimittel AG Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    The List of Tables and Figures (Totals 82 Figures and 128 Tables)

    • Figure Product Picture

    • Figure Europe Peptides Biosimilars Market Size and Growth Rate of Glucagon from 2014 to 2026

    • Figure Europe Peptides Biosimilars Market Size and Growth Rate of Calcitonin from 2014 to 2026

    • Figure Europe Peptides Biosimilars Market Size and Growth Rate of Oncology from 2014 to 2026

    • Figure Europe Peptides Biosimilars Market Size and Growth Rate of Chronic Diseases from 2014 to 2026

    • Figure Europe Peptides Biosimilars Market Size and Growth Rate of Autoimmune Diseases from 2014 to 2026

    • Figure Europe Peptides Biosimilars Market Size and Growth Rate of Blood Disorders from 2014 to 2026

    • Figure Europe Peptides Biosimilars Market Size and Growth Rate of Growth Hormone Deficiency from 2014 to 2026

    • Figure Europe Peptides Biosimilars Market Size and Growth Rate of Infectious Diseases from 2014 to 2026

    • Figure Europe Peptides Biosimilars Market Size and Growth Rate of Other Diseases from 2014 to 2026

    • Figure Germany Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure UK Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure France Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Peptides Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Peptides Biosimilars Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Peptides Biosimilars

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Peptides Biosimilars by Different Types from 2014 to 2026

    • Table Consumption Share of Peptides Biosimilars by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Glucagon

    • Figure Market Size and Growth Rate of Calcitonin

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Peptides Biosimilars by Different End-Users from 2014 to 2026

    • Table Consumption Share of Peptides Biosimilars by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Oncology

    • Figure Market Size and Growth Rate of Chronic Diseases

    • Figure Market Size and Growth Rate of Autoimmune Diseases

    • Figure Market Size and Growth Rate of Blood Disorders

    • Figure Market Size and Growth Rate of Growth Hormone Deficiency

    • Figure Market Size and Growth Rate of Infectious Diseases

    • Figure Market Size and Growth Rate of Other Diseases

    • Table Europe Peptides Biosimilars Production by Major Regions

    • Table Europe Peptides Biosimilars Production Share by Major Regions

    • Figure Europe Peptides Biosimilars Production Share by Major Countries and Regions in 2014

    • Table Europe Peptides Biosimilars Consumption by Major Regions

    • Table Europe Peptides Biosimilars Consumption Share by Major Regions

    • Table Germany Peptides Biosimilars Production, Import, Consumption and Export Analysis

    • Table UK Peptides Biosimilars Production, Import, Consumption and Export Analysis

    • Table France Peptides Biosimilars Production, Import, Consumption and Export Analysis

    • Table Italy Peptides Biosimilars Production, Import, Consumption and Export Analysis

    • Table Spain Peptides Biosimilars Production, Import, Consumption and Export Analysis

    • Table Poland Peptides Biosimilars Production, Import, Consumption and Export Analysis

    • Table Russia Peptides Biosimilars Production, Import, Consumption and Export Analysis

    • Table Switzerland Peptides Biosimilars Production, Import, Consumption and Export Analysis

    • Table Turkey Peptides Biosimilars Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Peptides Biosimilars Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Peptides Biosimilars Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Peptides Biosimilars Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Peptides Biosimilars Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Peptides Biosimilars Consumption by Types from 2014 to 2026

    • Table Germany Peptides Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Germany Peptides Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Germany Peptides Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table UK Peptides Biosimilars Consumption by Types from 2014 to 2026

    • Table UK Peptides Biosimilars Consumption Share by Types from 2014 to 2026

    • Table UK Peptides Biosimilars Consumption by End-Users from 2014 to 2026

    • Table UK Peptides Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table France Peptides Biosimilars Consumption by Types from 2014 to 2026

    • Table France Peptides Biosimilars Consumption Share by Types from 2014 to 2026

    • Table France Peptides Biosimilars Consumption by End-Users from 2014 to 2026

    • Table France Peptides Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Italy Peptides Biosimilars Consumption by Types from 2014 to 2026

    • Table Italy Peptides Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Italy Peptides Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Italy Peptides Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Spain Peptides Biosimilars Consumption by Types from 2014 to 2026

    • Table Spain Peptides Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Spain Peptides Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Spain Peptides Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Poland Peptides Biosimilars Consumption by Types from 2014 to 2026

    • Table Poland Peptides Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Poland Peptides Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Poland Peptides Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Russia Peptides Biosimilars Consumption by Types from 2014 to 2026

    • Table Russia Peptides Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Russia Peptides Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Russia Peptides Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Peptides Biosimilars Consumption by Types from 2014 to 2026

    • Table Switzerland Peptides Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Switzerland Peptides Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Switzerland Peptides Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Peptides Biosimilars Consumption by Types from 2014 to 2026

    • Table Turkey Peptides Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Turkey Peptides Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Turkey Peptides Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Peptides Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Peptides Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Peptides Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Peptides Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Peptides Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Peptides Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Peptides Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Peptides Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Peptides Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Peptides Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Peptides Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Peptides Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Peptides Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Peptides Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Samsung Biologics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Samsung Biologics

    • Figure Sales and Growth Rate Analysis of Samsung Biologics

    • Figure Revenue and Market Share Analysis of Samsung Biologics

    • Table Product and Service Introduction of Samsung Biologics

    • Table Company Profile and Development Status of Amgen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amgen

    • Figure Sales and Growth Rate Analysis of Amgen

    • Figure Revenue and Market Share Analysis of Amgen

    • Table Product and Service Introduction of Amgen

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Mylan

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Mylan

    • Figure Sales and Growth Rate Analysis of Mylan

    • Figure Revenue and Market Share Analysis of Mylan

    • Table Product and Service Introduction of Mylan

    • Table Company Profile and Development Status of Sandoz

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sandoz

    • Figure Sales and Growth Rate Analysis of Sandoz

    • Figure Revenue and Market Share Analysis of Sandoz

    • Table Product and Service Introduction of Sandoz

    • Table Company Profile and Development Status of Biocon

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Biocon

    • Figure Sales and Growth Rate Analysis of Biocon

    • Figure Revenue and Market Share Analysis of Biocon

    • Table Product and Service Introduction of Biocon

    • Table Company Profile and Development Status of Teva Pahrmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Teva Pahrmaceutical

    • Figure Sales and Growth Rate Analysis of Teva Pahrmaceutical

    • Figure Revenue and Market Share Analysis of Teva Pahrmaceutical

    • Table Product and Service Introduction of Teva Pahrmaceutical

    • Table Company Profile and Development Status of Celltrion

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Celltrion

    • Figure Sales and Growth Rate Analysis of Celltrion

    • Figure Revenue and Market Share Analysis of Celltrion

    • Table Product and Service Introduction of Celltrion

    • Table Company Profile and Development Status of Stada Arzneimittel AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Stada Arzneimittel AG

    • Figure Sales and Growth Rate Analysis of Stada Arzneimittel AG

    • Figure Revenue and Market Share Analysis of Stada Arzneimittel AG

    • Table Product and Service Introduction of Stada Arzneimittel AG

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US